C-Suite Women in Greater Philly’s Life Science Scene You Should Know

Published on :

As long overdue change takes shape and the number of women in the biotech industry continues to grow, it is important to recognize those that have created the path for the next generation of diverse leaders. BioBuzz wishes to acknowledge the incredible contributions and efforts of women who have made their mark on the industry. 

Center for Breakthrough Medicines (CBM) and jCyte Announce Strategic Partnership to Manufacture jCyte’s Innovative Cell Therapy for Treatment of Retinal Degenerative Diseases

Published on :

The Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing the unique requirements associated with commercializing cell and gene therapies, and jCyte, a clinical-stage biotech company focused on preserving and restoring vision in patients with retinitis pigmentosa (RP) and other retinal degenerative diseases, today announced a multi-year manufacturing agreement wherein CBM will be the primary manufacturer of jCyte’s U.S. Food & Drug Administration’s Regenerative Medicine Advanced Therapy (RMAT) designated cell therapy, jCell. Under the terms of the agreement, CBM will provide Phase 3 clinical trial supplies and commercial drug product following Biologics License Application (BLA) approval of jCyte’s proprietary jCell platform technology. CBM will also provide all BLA-enabling Chemistry, Manufacturing and Controls (CMC) work to support the program through regulatory approval and commercialization.

5 Questions With Shailah Yazdani, Director of Operations at the Center for Breakthrough Medicines

Published on :

Passionate about driving the next generation of provider and patient care offerings, Shailah Yazdani has dedicated more than 15 years to creating and modernizing organizational systems and delivering best-in-class healthcare solutions. Focusing on the company vision and mission, Shailah works with industry leaders to solve multi-layered challenges, designing innovative systems to create value and ignite enterprise growth.

Center for Breakthrough Medicines, QIAGEN Team Up to Raise Funds for Emily Whitehead Foundation

Published on :

Since Kymriah’s first approval in 2017, six CAR T-cell therapies have been approved by the FDA, all for different forms of blood cancer, such as lymphomas, leukemia, and multiple myeloma. As Gottlieb predicted, cell therapies have provided significant hope for cancer patients, both young and old, with many of them enjoying results they had not experienced with other therapies.

Life Science Leaders Share Optimism, Discuss Opportunities at Philadelphia Life Science Summit

Published on :

The buzz around the summit was one of enthusiasm as Philly strives to join the top tier of life sciences hub in the country. The life sciences scene in Philly is growing and may soon be approaching an inflection point preceding rapid growth, reminiscent of 1990s Boston. The Summit examined the dynamic Philly landscape as a whole, both celebrating recent successes and talk about the hurdles that must be overcome for the ecosystem to truly thrive.

Center for Breakthrough Medicines Plans for an Even Larger Dive into Cell Therapy Manufacturing

Published on :

As the pipeline for cell ther­a­pies grows, man­u­fac­tur­ers and CD­MOs are look­ing to get in on the ac­tion.
The Cen­ter for Break­through Med­i­cines, a Penn­syl­va­nia-based CD­MO, is part­ner­ing with Dis­cov­ery Labs to ac­cel­er­ate plans to build the ca­pac­i­ty to man­u­fac­ture more than 10,000 pa­tient ther­a­pies at their head­quar­ters in King of Prus­sia, PA, a sub­urb of Philadel­phia.
The plan­ning has be­gun on the man­u­fac­tur­ing suites and sup­port­ing in­fra­struc­ture, and when com­plet­ed the fa­cil­i­ty, ac­cord­ing to CBM’s con­ser­v­a­tive cal­cu­la­tions, the site will be able to pro­duce around 10,000 batch­es of prod­uct per year in the space.

Center for Breakthrough Medicines Accelerates Plans to Build the Largest Cell Therapy Manufacturing Operation in the World

Published on :

The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs announced today the acceleration of plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer.

Center for Breakthrough Medicine Appoints Joseph Lingle as Chief People Officer

Published on :

The Center for Breakthrough Medicines (CBM) announced today the appointment of Joseph (Joe) Lingle as Chief People Officer. In his role, Lingle will oversee all Human Resources (HR) activities, including talent management, workplace experience, and Diversity, Equity, and Inclusion (DE&I).

Philly Life Science Companies Bring Home the Gold at PACT’s 29th Annual Enterprise Awards

Published on :

After yet another year with COVID-19, the Greater Philadelphia Alliance for Capital and Technology (PACT) knew Philly entrepreneurs needed a reason to celebrate, IRL.
PACT gathers industry leaders, growing companies and local institutions each year for its Enterprise Awards celebrating innovators in the tech and life sciences community. 2021’s event was the first back after a pandemic hiatus and honored investor and serial entrepreneur Josh Kopelman with a Legend Award.
This year, for its 29th edition, PACT convened folks at the Springfield Country Club in Delaware County on Tuesday, May 24, to honor 27 people and organizations. Though there was no Legend Award this time around, nine companies and people took home awards.

Center for Breakthrough Medicines Beats Back on the 2022 Biotech Bear Market with Rapid Hiring and Expansion

Published on :

Audrey Greenberg, co-founder of CBM and also the executive director of The Discovery Labs, said the successful growth seen at CBM is a testament to the great company culture the organization has built since its founding in 2019. Among the hires in the first quarter of this year is John Lee, PhD, the new Vice President and Head of Cell Therapy. Lee, an accomplished CAR-T immunobiologist, was hired in March to lead cell therapy programs at CBM. Prior to joining CBM, Lee established the Cell Therapy Platform team at Janssen Pharmaceuticals. He also served as head of Oncology Cell Therapy at GlaxoSmithKline.